Entero Therapeutics subsidiary settles litigation, restructures $7.9M debt with $5.5M payment and new revolving loan

GridAI Technologies Corp.

ImmunogenX subsidiary settled lawsuit with Mattress Liquidators; guarantors paid $5.5M of ~$7.9M owed on Apr 9, 2025.
New revolving loan of $2.44M to ImmunogenX matures Apr 9, 2028; security interest in subsidiary released.
Lawsuit to be dismissed with prejudice; ImmunogenX responsible for ~$62,000 in plaintiff's legal fees.
Annual meeting June 27, 2025; stockholder proposals/director nominations due by May 23, 2025.

item 1.01 item 2.03 item 5.08 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-048544
form_type: 8-K
ticker: GRDX
cik: 0001604191
company_name: GridAI Technologies Corp.
filed_at: 2025-05-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.981783+00:00
generated_at: 2026-05-21T08:48:36.490679+00:00
sec_items: ["1.01", "2.03", "5.08", "9.01"]
event_type: litigation
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-048544
json_url: https://secwatch.observer/filing/0001104659-25-048544.json
markdown_url: https://secwatch.observer/filing/0001104659-25-048544.md
text_url: https://secwatch.observer/filing/0001104659-25-048544.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1604191/000110465925048544/0001104659-25-048544-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1604191/000110465925048544/tm2515026d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-048544

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.